Login / Signup

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson's Disease: An Open-Label, Pragmatic Trial.

Aryun KimYoung Eun KimJi Young YunHan-Joon KimHui-Jun YangWoong-Woo LeeChae Won ShinHyeyoung ParkYu Jin JungAhro KimYoon KimMihee JangBeom Seok Jeon
Published in: Journal of movement disorders (2018)
Amantadine as an initial treatment may decrease the incidence of dyskinesia in patients with drug-naïve PD.
Keyphrases
  • study protocol
  • clinical trial
  • risk factors
  • randomized controlled trial
  • emergency department
  • phase ii
  • open label
  • smoking cessation